Headquartered in San Diego, CA Fiscal year ends December NASDAQ: BOLD boundlessbio.com
Boundless Bio is a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, aiming to develop transformative therapies for patients with oncogene amplified cancers. The company's research centers on ecDNA, identified as a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Its lead program, BBI-940, is a potentially first-in-class oral selective Kinesin degrader designed as an ecDNA-directed therapeutic candidate (ecDTx). BBI-940 is currently being evaluated in the KOMODO-1 first-in-human clinical trial targeting ER+/HER2- breast cancer patients who have progressed on CDK4/6 inhibitors plus endocrine therapy, as well as patients with triple-negative breast cancer of the luminal androgen receptor subtype. The company is pre-revenue and trades on Nasdaq under the ticker BOLD. Updated
Do you have $1,500 you’d like to use to try investing in penny stocks? Some investments in the category can yield outsized gains. But you need to be aware of the risks…
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Audentes Therapeutics shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just over three years, this acquisition…
Chris Lange Tuesday's top analyst upgrades, downgrades and initiations included Alphabet, Amazon.com, Beyond Meat, CommScope, Enphase Energy, Nabors Industries, Netflix, Nike, Roku, Tesla, Uber Technologies and Williams Companies.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
Boundless Bio is a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, aiming to develop transformative therapies for patients with oncogene amplified cancers.
The Wall Street consensus 12-month price target for BOLD is $4.00.
